Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-vfjqv Total loading time: 0 Render date: 2024-04-28T07:02:20.124Z Has data issue: false hasContentIssue false

Chapter 18 - Genetics of Non-Motor Symptoms of Parkinson’s Disease

Published online by Cambridge University Press:  05 March 2022

By
Konstantin Senkevich ,
Roy N. Alcalay  and
Ziv Gan-Or
Edited by
Néstor Gálvez-Jiménez ,
Amos D. Korczyn  and
Ramón Lugo-Sanchez
Néstor Gálvez-Jiménez
Affiliation:
Florida International University
Amos D. Korczyn
Affiliation:
Tel-Aviv University
Ramón Lugo-Sanchez
Affiliation:
Cleveland Clinic
Get access

Summary

Parkinson’s disease (PD) has long been considered as a prototype of a sporadic disorder with little or no involvement of genetic factors. Three to four decades ago, the typical perception of genetics in PD was that “it appears unlikely that heredity is an important determinant in the development of the disorder” [1]. The discovery of SNCA mutations in 1997 [2] started a new era of genetic studies in PD. We now know of at least 90 independent genome-wide association study (GWAS) risk variants in 78 loci that are associated with sporadic PD [3]. Several other genes that are involved in familial, sporadic PD, or atypical forms of familial parkinsonism, have also been identified (Table 18.1).

Type
Chapter
Information
Non-motor Parkinson's Disease , pp. 199 - 211
Publisher: Cambridge University Press
Print publication year: 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Kopin, IJ, Markey, SP. MPTP toxicity: implications for research in Parkinson’s disease. Annu Rev Neurosci 1988; 11: 81–96.Google Scholar
Polymeropoulos, MH, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 1997; 276(5321): 2045–2047.CrossRefGoogle ScholarPubMed
Nalls, MA, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet Neurol 2019; 18(12): 1091–1102.Google Scholar
Gan-Or, Z, et al. Differential effects of severe vs mild GBA mutations on Parkinson disease. Neurology 2015; 84(9): 880–887.Google Scholar
Healy, DG, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurol 2008; 7(7): 583–590.CrossRefGoogle ScholarPubMed
Alcalay, RN, et al. Glucocerebrosidase activity in Parkinson’s disease with and without GBA mutations. Brain 2015; 138(Pt 9): 2648–2658.CrossRefGoogle ScholarPubMed
Gegg, ME, et al. Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains. Ann Neurol 2012; 72(3): 455–463.CrossRefGoogle ScholarPubMed
Lesage, S, Brice, A. Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009; 18(R1): R48–R59.CrossRefGoogle ScholarPubMed
Kilarski, LL, et al. Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson’s disease. Mov Disord 2012; 27(12): 1522–1529.Google Scholar
Blauwendraat, C, Nalls, MA, Singleton, AB. The genetic architecture of Parkinson’s disease. Lancet Neurol 2019; 19(2): 170–178.Google Scholar
Correia Guedes, L, et al. Are genetic and idiopathic forms of Parkinson’s disease the same disease? J Neurochem 2020; 152(5): 515–522.Google Scholar
Blauwendraat, C, et al. Parkinson’s disease age at onset genome-wide association study: defining heritability, genetic loci, and alpha-synuclein mechanisms. Mov Disord 2019; 34(6): 866–875.Google Scholar
Pfeiffer, RF. Non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord 2016; 22(Suppl 1): S119–S122.CrossRefGoogle ScholarPubMed
Seppi, K, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease: an evidence-based medicine review. Mov Disord 2019; 34(2): 180–198.Google Scholar
Barber, TR, et al. Prodromal parkinsonism and neurodegenerative risk stratification in REM sleep behavior disorder. Sleep 2017; 40(8).Google Scholar
Krohn, L, et al. Genetic, structural, and functional evidence link TMEM175 to synucleinopathies. Ann Neurol 2020; 87(1): 139–153.Google Scholar
Honeycutt, L, et al. Glucocerebrosidase mutations and phenoconversion of REM sleep behavior disorder to parkinsonism and dementia. Parkinsonism Relat Disord 2019; 65: 230–233.CrossRefGoogle ScholarPubMed
Ouled Amar Bencheikh, B, et al. LRRK2 protective haplotype and full sequencing study in REM sleep behavior disorder. Parkinsonism Relat Disord 2018; 52: 98–101.CrossRefGoogle ScholarPubMed
Li, J, et al. Full sequencing and haplotype analysis of MAPT in Parkinson’s disease and rapid eye movement sleep behavior disorder. Mov Disord 2018; 33(6): 1016–1020.Google Scholar
Gan-Or, Z, et al. The dementia-associated APOE epsilon4 allele is not associated with rapid eye movement sleep behavior disorder. Neurobiol Aging 2017; 49: 218.e13–218.e15.Google Scholar
Gan-Or, Z, et al. The role of the melanoma gene MC1 R in Parkinson disease and REM sleep behavior disorder. Neurobiol Aging 2016; 43: 180.e7–180.e13.CrossRefGoogle Scholar
Krohn, L, et al. Fine-mapping of SNCA in REM sleep behavior disorder and overt synucleinopathies. Ann Neurol 2020; 2020. doi:10.1002/ana.25687CrossRefGoogle Scholar
Krohn, L, et al. GBA variants in REM sleep behavior disorder: a multicenter study. “Neurology 2020; 95(8):e1008-e1016. doi: 10.1212/WNL.0000000000010042”Google Scholar
Blauwendraat, C, et al. Genetic modifiers of risk and age at onset in GBA associated Parkinson’s disease and Lewy body dementia. Brain 2020; 143(1): 234–248.Google Scholar
Schormair, B, et al. Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis. Lancet Neurol 2017; 16(11): 898–907.Google Scholar
Mohtashami, S, et al. TOX3 variants are involved in restless legs syndrome and Parkinson’s disease with opposite effects. J Mol Neurosci 2018; 64(3): 341–345.Google Scholar
Alonso-Navarro, H, et al. Association between restless legs syndrome and other movement disorders. Neurology 2019; 92(20): 948–964.Google Scholar
Gan-Or, Z, et al. Genetic markers of Restless Legs Syndrome in Parkinson disease. Parkinsonism Relat Disord 2015; 21(6): 582–585.Google Scholar
Knie, B, et al. Excessive daytime sleepiness in patients with Parkinson’s disease. CNS Drugs 2011; 25(3): 203–212.Google Scholar
Wang, H, et al. Genome-wide association analysis of self-reported daytime sleepiness identifies 42 loci that suggest biological subtypes. Nat Commun 2019; 10(1): 3503.Google Scholar
Zhu, K, van Hilten, JJ, Marinus, J. Course and risk factors for excessive daytime sleepiness in Parkinson’s disease. Parkinsonism Relat Disord 2016; 24: 34–40.CrossRefGoogle ScholarPubMed
Iwaki, H, et al. Genetic risk of Parkinson disease and progression: an analysis of 13 longitudinal cohorts. Neurol Genet 2019; 5(4): e348.Google Scholar
Lin, CY, et al. Effect of ALDH2 on sleep disturbances in patients with Parkinson’s disease. Sci Rep 2019; 9(1): 18950.Google Scholar
Yeung, EYH, Cavanna, AE. Sleep attacks in patients with Parkinson’s disease on dopaminergic medications: a systematic review. Mov Disord Clin Pract 2014; 1(4): 307–316.Google Scholar
Iwaki, H, et al. Genomewide association study of Parkinson’s disease clinical biomarkers in 12 longitudinal patients’ cohorts. Mov Disord 2019; 34(12): 1839–1850.Google Scholar
Chahine, LM, Amara, AW, Videnovic, A. A systematic review of the literature on disorders of sleep and wakefulness in Parkinson’s disease from 2005 to 2015. Sleep Med Rev 2017; 35: 33–50.Google Scholar
Jansen, PR, et al. Genome-wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and functional pathways. Nat Genet 2019; 51(3): 394–403.Google Scholar
Fagan, ES, Pihlstrom, L. Genetic risk factors for cognitive decline in Parkinson’s disease: a review of the literature. Eur J Neurol 2017; 24(4): 561-e20.Google Scholar
Koros, C, et al. Selective cognitive impairment and hyposmia in p.A53 T SNCA PD vs typical PD. Neurology 2018; 90(10): e864–e869.Google Scholar
Piredda, R, et al. Cognitive and psychiatric symptoms in genetically determined Parkinson’s disease: a systematic review. Eur J Neurol 2019; 27(2): 229–234.CrossRefGoogle Scholar
Guella, I, et al. Alpha-synuclein genetic variability: a biomarker for dementia in Parkinson disease. Ann Neurol 2016; 79(6): 991–999.Google Scholar
Corrado, L, et al. The length of SNCA rep1 microsatellite may influence cognitive evolution in Parkinson’s disease. Front Neurol 2018; 9: 213.Google Scholar
Alcalay, RN, et al. Neuropsychological performance in LRRK2 G2019S carriers with Parkinson’s disease. Parkinsonism Relat Disord 2015; 21(2): 106–110.Google Scholar
Srivatsal, S, et al. Cognitive profile of LRRK2-related Parkinson’s disease. Mov Disord 2015; 30(5): 728–733.Google Scholar
Alcalay, RN, et al. Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations. Mov Disord 2013; 28(14): 1966–1971.Google Scholar
Alcalay, RN, et al. Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson’s disease. J Clin Exp Neuropsychol 2010; 32(7): 775–779.Google Scholar
Shanker, V, et al. Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson’s disease. Mov Disord 2011; 26(10): 1875–1880.Google Scholar
Alcalay, RN, et al. Cognitive and motor function in long-duration PARKIN-associated Parkinson disease. JAMA Neurol 2014; 71(1): 62–67.Google Scholar
Hassin-Baer, S, et al. Phenotype of the 202 adenine deletion in the parkin gene: 40 years of follow-up. Mov Disord 2011; 26(4): 719–722.CrossRefGoogle Scholar
Cilia, R, et al. Survival and dementia in GBA-associated Parkinson’s disease: the mutation matters. Ann Neurol 2016; 80(5): 662–673.Google Scholar
Alcalay, RN, et al. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology 2012; 78(18): 1434–1440.Google Scholar
Bras, J, et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet 2014; 23(23): 6139–6146.Google Scholar
Neumann, J, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease. Brain 2009; 132(Pt 7): 1783–1794.Google Scholar
Clark, LN, et al. Association of glucocerebrosidase mutations with dementia with lewy bodies. Arch Neurol 2009; 66(5): 578–583.Google Scholar
Wong, K, et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab 2004; 82(3): 192–207.Google Scholar
Postuma, RB, et al. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology 2015; 84(11): 1104–1113.Google Scholar
Creese, B, et al. Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson’s disease and Lewy body dementias: review and meta-analyses. Am J Med Genet B Neuropsychiatr Genet 2018; 177(2): 232–241.CrossRefGoogle ScholarPubMed
Mata, IF, et al. Large-scale exploratory genetic analysis of cognitive impairment in Parkinson’s disease. Neurobiol Aging 2017; 56: 211.e1–211.e7.Google Scholar
Pierzchlinska, A, et al. The impact of Apolipoprotein E alleles on cognitive performance in patients with Parkinson’s disease. Neurol Neurochir Pol 2018; 52(4): 477–482.Google Scholar
Pang, S, et al. Meta-analysis of the relationship between the APOE gene and the onset of Parkinson’s disease dementia. Parkinsons Dis 2018; 2018: 9497147.Google Scholar
Bialecka, M, et al. Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson’s disease. Pharmacogenet Genomics 2012; 22(10): 716–724.Google Scholar
Tang, C, et al. Meta-analysis of the effects of the catechol-O-methyltransferase Val158/108 met polymorphism on Parkinson’s disease susceptibility and cognitive dysfunction. Front Genet 2019; 10: 644.Google Scholar
Gao, YL, et al. Tau in neurodegenerative disease. Ann Transl Med 2018; 6(10): 175.Google Scholar
Goris, A, et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson’s disease. Ann Neurol 2007; 62(2): 145–153.Google Scholar
Seto-Salvia, N, et al. Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. Arch Neurol 2011; 68(3): 359–364.Google Scholar
Winder-Rhodes, SE, et al. Association between MAPT haplotype and memory function in patients with Parkinson’s disease and healthy aging individuals. Neurobiol Aging 2015; 36(3): 1519–1528.Google Scholar
Nombela, C, et al. Genetic impact on cognition and brain function in newly diagnosed Parkinson’s disease: ICICLE-PD study. Brain 2014; 137(Pt 10): 2743–2758.Google Scholar
Shen, T, et al. BDNF polymorphism: a review of its diagnostic and clinical relevance in neurodegenerative disorders. Aging Dis 2018; 9(3): 523–536.Google Scholar
Aarsland, D, Kramberger, MG. Neuropsychiatric symptoms in Parkinson’s disease. J Parkinsons Dis 2015; 5(3): 659–667.Google Scholar
Brockmann, K, et al. GBA-associated PD presents with nonmotor characteristics. Neurology 2011; 77(3): 276–280.Google Scholar
Swan, M, et al. Neuropsychiatric characteristics of GBA-associated Parkinson disease. J Neurol Sci 2016; 370: 63–69.Google Scholar
Malek, N, et al. Features of GBA-associated Parkinson’s disease at presentation in the UK Tracking Parkinson’s study. J Neurol Neurosurg Psychiatry 2018; 89(7): 702–709.Google Scholar
Wang, C, et al. Clinical profiles of Parkinson’s disease associated with common leucine-rich repeat kinase 2 and glucocerebrosidase genetic variants in Chinese individuals. Neurobiol Aging 2014; 35(3): 725.e1–725.e6.Google Scholar
Song, J, et al. Non-motor symptoms in Parkinson’s disease patients with Parkin mutations: more depression and less executive dysfunction. J Mol Neurosci 2020; 70: 246–253.CrossRefGoogle Scholar
Abou-Sleiman, PM, et al. The role of pathogenic DJ-1 mutations in Parkinson’s disease. Ann Neurol 2003; 54(3): 283–286.Google Scholar
Ricciardi, L, et al. Phenotypic variability of PINK1 expression: 12 years’ clinical follow-up of two Italian families. Mov Disord 2014; 29(12): 1561–1566.Google Scholar
Bonifati, V, et al. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 2005; 65(1): 87–95.Google Scholar
Ephraty, L, et al. Neuropsychiatric and cognitive features in autosomal-recessive early parkinsonism due to PINK1 mutations. Mov Disord 2007; 22(4): 566–569.Google Scholar
Thaler, A, et al. Parkinson’s disease phenotype is influenced by the severity of the mutations in the GBA gene. Parkinsonism Relat Disord 2018; 55: 45–49.Google Scholar
Kasten, M, Klein, C. The many faces of alpha-synuclein mutations. Mov Disord 2013; 28(6): 697–701.Google Scholar
Song, J, et al. Non-motor symptoms in Parkinson’s disease patients with Parkin mutations: more depression and less executive dysfunction. J Mol Neurosci 2020: p. 10.1007/s12031-019–01444–3.Google Scholar
Khan, NL, et al. Parkin disease: a phenotypic study of a large case series. Brain 2003; 126(Pt 6): 1279–1292.Google Scholar
Struhal, W, et al. VPS35 Parkinson’s disease phenotype resembles the sporadic disease. J Neural Transm 2014; 121(7): 755–759.Google Scholar
D’Souza, T, Rajkumar, AP. Systematic review of genetic variants associated with cognitive impairment and depressive symptoms in Parkinson’s disease. Acta Neuropsychiatr 2019; 32(1): 10–22.Google Scholar
Cagni, FC, et al. Association of BDNF Val66 MET polymorphism with Parkinson’s disease and depression and anxiety symptoms. J Neuropsychiatry Clin Neurosci 2017; 29(2): 142–147.CrossRefGoogle Scholar
Zheng, J, et al. Association between gene polymorphism and depression in Parkinson’s disease: a case-control study. J Neurol Sci 2017; 375: 231–234.Google Scholar
Hua, P, et al. Association of Tef polymorphism with depression in Parkinson disease. Mov Disord 2012; 27(13): 1694–1697.Google Scholar
Barrero, FJ, et al. Depression in Parkinson’s disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). The Pharmacogenomics J 2005; 5(2): 135–141.CrossRefGoogle ScholarPubMed
Chang, J, et al. ApoE ε4 allele is associated with incidental hallucinations and delusions in patients with AD. Neurology 2004; 63(6): 1105–1107.Google Scholar
Lenka, A, et al. Genetic substrates of psychosis in patients with Parkinson’s disease: a critical review. J Neurol Sci 2016; 364: 33–41.Google Scholar
Papapetropoulos, S, et al. Phenotypic associations of tau and ApoE in Parkinson’s disease. Neurosci Lett 2007; 414(2): 141–144.Google Scholar
Cormier-Dequaire, F, et al. Suggestive association between OPRM1 and impulse control disorders in Parkinson’s disease. Mov Disord 2018; 33(12): 1878–1886.CrossRefGoogle ScholarPubMed
Ffytche, DH, et al. The psychosis spectrum in Parkinson disease. Nat Rev Neurol 2017; 13(2): 81–95.Google Scholar
Morgante, F, et al. Impulsive-compulsive behaviors in parkin-associated Parkinson disease. Neurology 2016; 87(14): 1436–1441.Google Scholar
Sharp, ME, et al. The relationship between obsessive-compulsive symptoms and PARKIN genotype: the CORE-PD study. Mov Disord 2015; 30(2): 278–283.Google Scholar
Ricciardi, L, et al. Phenotypic variability of PINK1 expression: 12 years’ clinical follow-up of two Italian families. Mov Disord 2014; 29(12): 1561–1566.Google Scholar
Ephraty, L, et al. Neuropsychiatric and cognitive features in autosomal-recessive early parkinsonism due to PINK1 mutations. Mov Disord 2007; 22(4): 566–569.Google Scholar
Bhattacharjee, S. Impulse control disorders in Parkinson’s disease: review of pathophysiology, epidemiology, clinical features, management, and future challenges. Neurol India 2018; 66(4): 967–975.CrossRefGoogle ScholarPubMed
Dong, J, et al. Genome-wide association analysis of the sense of smell in U.S. older adults: identification of novel risk loci in African-Americans and European-Americans. Mol Neurobiol 2017; 54(10): 8021–8032.Google Scholar
Shu, L, et al. Clinical heterogeneity among LRRK2 variants in Parkinson’s disease: a meta-analysis. Front Aging Neurosci 2018; 10: 283.Google Scholar
Wang, Y, et al. Olfaction in Parkin carriers in Chinese patients with Parkinson disease. Brain Behav 2017; 7(5): e00680.Google Scholar
Avenali, M, et al. Evolution of prodromal parkinsonian features in a cohort of GBA mutation-positive individuals: a 6-year longitudinal study. J Neurol Neurosurg Psychiatry 2019; 90(10): 1091–1097.Google Scholar
Thaler, A, et al. A “dose” effect of mutations in the GBA gene on Parkinson’s disease phenotype. Parkinsonism Relat Disord 2017; 36: 47–51.Google Scholar
Kagi, G, et al. Nonmotor symptoms in Parkin gene-related parkinsonism. Mov Disord 2010; 25(9): 1279–1284.Google Scholar
Brockmann, K, et al. GBA-associated PD presents with nonmotor characteristics. Neurology 2011; 77(3): 276–280.Google Scholar
Li, Y, et al. Clinicogenetic study of GBA mutations in patients with familial Parkinson’s disease. Neurobiol Aging 2014; 35(4): 935.e3–8.Google Scholar
Redenšek, S, et al. Dopaminergic pathway genes influence adverse events related to dopaminergic treatment in Parkinson’s disease. Front Pharmacol 2019; 10: 8.Google Scholar
Antonini, A, et al. Pain in Parkinson’s disease: facts and uncertainties. Eur J Neurol 2018; 25(7): 917-e69.Google Scholar
Ha, AD, Jankovic, J. Pain in Parkinson’s disease. Mov Disord 2012; 27(4): 485–491.Google Scholar
Greenbaum, L, et al. Contribution of genetic variants to pain susceptibility in Parkinson disease. Eur J Pain 2012; 16(9): 1243–1250.Google Scholar
Duan, G, et al. The effect of SCN9A variation on basal pain sensitivity in the general population: an experimental study in young women. J Pain 2015; 16(10): 971–980.Google Scholar
Lin, C-H, et al. Depression and catechol-O-methyltransferase (COMT) genetic variants are associated with pain in Parkinson’s disease. Sci Rep 2017; 7(1): 6306.Google Scholar
Kresojević, N, et al. Presenting symptoms of GBA-related Parkinson’s disease. Parkinsonism Relat Disord 2015; 21(7): 804–807.Google Scholar
Simuni, T, et al. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson’s Progression Markers Initiative (PPMI): a cross-sectional study. Lancet Neurol 2020; 19(1): 71–80.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×